Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA2: Adjuvant Osimertinib in Stage IA2-IA3 EGFRm NSCLC
NCT05120349Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib 80 mg with Placebo (2 arms). Primary endpoint: Disease-Free Survival in high-risk stratum. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05120349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120349.